193 related articles for article (PubMed ID: 29423106)
1. The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells.
Dey S; Kumari S; Kalainayakan SP; Campbell J; Ghosh P; Zhou H; FitzGerald KE; Li M; Mason RP; Zhang L; Liu L
Oncotarget; 2018 Jan; 9(3):4090-4101. PubMed ID: 29423106
[TBL] [Abstract][Full Text] [Related]
2. Predicting Clinical Efficacy of Vascular Disrupting Agents in Rodent Models of Primary and Secondary Liver Cancers: An Overview with Imaging-Histopathology Correlation.
Liu Y; Wang S; Zhao X; Feng Y; Bormans G; Swinnen J; Oyen R; Huang G; Ni Y; Li Y
Diagnostics (Basel); 2020 Jan; 10(2):. PubMed ID: 32024029
[TBL] [Abstract][Full Text] [Related]
3. The development and use of vascular targeted therapy in ovarian cancer.
Chase DM; Chaplin DJ; Monk BJ
Gynecol Oncol; 2017 May; 145(2):393-406. PubMed ID: 28238563
[TBL] [Abstract][Full Text] [Related]
4. A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor.
Liu T; Zhang D; Song W; Tang Z; Zhu J; Ma Z; Wang X; Chen X; Tong T
Acta Biomater; 2017 Apr; 53():179-189. PubMed ID: 28167300
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive Anatomical and Functional Imaging of Orthotopic Glioblastoma Development and Therapy using Multispectral Optoacoustic Tomography.
Balasundaram G; Ding L; Li X; Attia ABE; Dean-Ben XL; Ho CJH; Chandrasekharan P; Tay HC; Lim HQ; Ong CB; Mason RP; Razansky D; Olivo M
Transl Oncol; 2018 Oct; 11(5):1251-1258. PubMed ID: 30103155
[TBL] [Abstract][Full Text] [Related]
6. Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging.
McPhail LD; Griffiths JR; Robinson SP
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1238-45. PubMed ID: 17967313
[TBL] [Abstract][Full Text] [Related]
7. Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using MRI-based vessel size imaging.
Nielsen T; Bentzen L; Pedersen M; Tramm T; Rijken PF; Bussink J; Horsman MR; Østergaard L
Clin Cancer Res; 2012 Dec; 18(23):6469-77. PubMed ID: 23071260
[TBL] [Abstract][Full Text] [Related]
8. Reverse micelles-in-microspheres with sustained release of water-soluble combretastatin A4 phosphate for S180 tumor treatment.
Wu L; Qiu L
J Mater Chem B; 2016 Jan; 4(4):760-767. PubMed ID: 32262957
[TBL] [Abstract][Full Text] [Related]
9. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice.
Welford AF; Biziato D; Coffelt SB; Nucera S; Fisher M; Pucci F; Di Serio C; Naldini L; De Palma M; Tozer GM; Lewis CE
J Clin Invest; 2011 May; 121(5):1969-73. PubMed ID: 21490397
[TBL] [Abstract][Full Text] [Related]
10. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer.
Ng QS; Goh V; Carnell D; Meer K; Padhani AR; Saunders MI; Hoskin PJ
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1375-80. PubMed ID: 17275203
[TBL] [Abstract][Full Text] [Related]
11. An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate.
Williams LJ; Mukherjee D; Fisher M; Reyes-Aldasoro CC; Akerman S; Kanthou C; Tozer GM
Br J Pharmacol; 2014 Nov; 171(21):4902-13. PubMed ID: 24930520
[TBL] [Abstract][Full Text] [Related]
12. Micro-HCCs in rats with liver cirrhosis: paradoxical targeting effects with vascular disrupting agent CA4P.
Liu Y; Yin T; Keyzer F; Feng Y; Chen F; Liu J; Song S; Yu J; Vandecaveye V; Swinnen J; Bormans G; Himmelreich U; Oyen R; Zhang J; Huang G; Ni Y
Oncotarget; 2017 Aug; 8(33):55204-55215. PubMed ID: 28903414
[TBL] [Abstract][Full Text] [Related]
13. Vascular disrupting effect of combretastatin A-4 phosphate with inhibition of vascular endothelial cadherin in canine osteosarcoma-xenografted mice.
Izumi Y; Takagi S
Res Vet Sci; 2019 Feb; 122():1-6. PubMed ID: 30439557
[TBL] [Abstract][Full Text] [Related]
14. Water-Soluble Combretastatin A4 Phosphate Orally Delivered via Composite Nanoparticles With Improved Inhibition Effect Toward S180 Tumors.
Shen Y; Wu L; Qiu L
J Pharm Sci; 2017 Oct; 106(10):3076-3083. PubMed ID: 28619603
[TBL] [Abstract][Full Text] [Related]
15. Oxygen-Enhanced Optoacoustic Tomography Reveals the Effectiveness of Targeting Heme and Oxidative Phosphorylation at Normalizing Tumor Vascular Oxygenation.
Ghosh P; Guo Y; Ashrafi A; Chen J; Dey S; Zhong S; Liu J; Campbell J; Konduri PC; Gerberich J; Garrossian M; Mason RP; Zhang L; Liu L
Cancer Res; 2020 Sep; 80(17):3542-3555. PubMed ID: 32546631
[TBL] [Abstract][Full Text] [Related]
16. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.
Salmon HW; Siemann DW
Clin Cancer Res; 2006 Jul; 12(13):4090-4. PubMed ID: 16818709
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management.
Grisham R; Ky B; Tewari KS; Chaplin DJ; Walker J
Gynecol Oncol Res Pract; 2018; 5():1. PubMed ID: 29318022
[TBL] [Abstract][Full Text] [Related]
18. Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate.
Lunt SJ; Akerman S; Hill SA; Fisher M; Wright VJ; Reyes-Aldasoro CC; Tozer GM; Kanthou C
Int J Cancer; 2011 Oct; 129(8):1979-89. PubMed ID: 21154772
[TBL] [Abstract][Full Text] [Related]
19. A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers.
Abma E; De Spiegelaere W; Vanderperren K; Stock E; Van Brantegem L; Cornelis I; Daminet S; Ni Y; Vynck M; Verstraete G; Smets P; de Rooster H
Vet Comp Oncol; 2018 Dec; 16(4):467-477. PubMed ID: 29797763
[TBL] [Abstract][Full Text] [Related]
20. Combretastatin A4 phosphate: a novel vascular disrupting agent.
Nagaiah G; Remick SC
Future Oncol; 2010 Aug; 6(8):1219-28. PubMed ID: 20799867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
